Company

About

Evergen (formerly TissX LLC)

Evergen (formerly TissX LLC)

3405 Annapolis Ln N, Plymouth, Minnesota, US

Tissx sources, manufactures and supplies tissue products and services for cardiac, vascular and other specialty surgeries. Our goal is to make affordable high quality tissue products available worldwide. We develop and manufacture products including fixed pericardial tissue patches and valve repair products. Tissx also works with corporations to source and supply tissue, provide OEM services and develop tissue bioprosthetics.

Ponte Biosciences, Inc.

Ponte Biosciences, Inc.

3555 9th St NW , 250, Rochester, MN 55901, US

Ponte Biosciences, Inc. is a preclinical biotherapeutic company focused on developing a cell-based bioartificial liver system to treat acute forms of liver failure. The Company's Spheroid Reservoir Bioartificial Liver (SRBAL) system was developed at the Mayo Clinic and utilizes metabolically active primary hepatocytes (liver cells) to replace and/or supplement liver function for patients with liver failure being treated in the Intensive Care Unit (ICU).

Vascudyne Inc

Vascudyne Inc

296 Chester St, St Paul, Minnesota 55107, US

Vascudyne Inc is a biotechnology company based in Minnesota, focused on regenerative medicine through engineered biological tissues. Founded in 2014 and headquartered in Stillwater, with operations in Saint Paul, Vascudyne develops acellular in-vitro grown allograft tissues that mimic the properties of natural human tissue. The company’s TRUE™ Tissue Technology is a proprietary platform that produces 100% biological soft tissue implants. Their product portfolio includes the TRUE™ Graft for vascular access in hemodialysis, the TRUE™ Valve for engineered valved conduits, and the TRUE™ Patch for tissue repair. Vascudyne emphasizes the use of biologically derived extracellular matrix materials and tunable anisotropic tensile properties in their manufacturing processes. Vascudyne has achieved significant milestones, including successful First-in-Human studies for the TRUE™ Graft and preclinical validations for their products. The company operates within Minnesota’s "Medical Alley," benefiting from the region's medtech ecosystem, and has raised a total of $19.63 million in funding to support its innovative work in regenerative biomaterials.